AKBA
Akebia Therapeutics, Inc.
Price Chart
Latest Quote
$0.94
-0.04 (-3.61%)
Current Price
| Previous Close | $0.97 |
| Open | $0.96 |
| Day High | $0.99 |
| Day Low | $0.93 |
| Volume | 1,836,798 |
Stock Information
| Shares Outstanding | 268.26M |
| Total Debt | $197.52M |
| Cash Equivalents | $162.64M |
| Revenue | $232.40M |
| Net Income | $-20.51M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $250.90M |
| EPS (TTM) | $-0.08 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $285.78M |
| Sales | $232.40M |
| Income | $-20.51M |
| Book/sh | $0.10 |
| Cash/sh | $0.61 |
| Employees | 194 |
Financial Ratios
| Quick Ratio | 1.29 |
| Current Ratio | 1.40 |
| Debt/Eq | 721.55 |
Returns & Margins
| ROA | 2.02% |
| ROE | -78.95% |
| Gross Margin | 81.94% |
| Operating Margin | -2.76% |
| Profit Margin | -8.83% |
Ownership
| Insider Ownership | 4.00% |
| Institutional Ownership | 42.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.92 |
| P/S | 1.08 |
| P/B | 9.17 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $4.20 |
Technical Indicators
| SMA20 | $1.04 |
| SMA50 | $1.26 |
| SMA200 | $1.81 |
| RSI | 38.05 |
| ATR | 0.0704 |
| Shares Float | 262.29M |
| Short Float | 9.98% |
| Short Ratio | 7.54 |
| Volatility | 0.25 |
| Rel Volume | 0.35 |
Performance History
| Week | -8.33% |
| Month | -36.82% |
| Quarter | -26.38% |
| 6 Months | -40.45% |
| YTD | -39.68% |
| Year | -74.31% |
| 3 Years | -10.10% |
| 5 Years | -73.36% |
| 10 Years | -89.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.94 | 1,847,600 |
| 2026-06-04 | $0.97 | 2,392,900 |
| 2026-06-03 | $0.97 | 4,549,200 |
| 2026-06-02 | $0.94 | 7,220,200 |
| 2026-06-01 | $1.02 | 2,756,700 |
| 2026-05-29 | $1.02 | 2,702,600 |
| 2026-05-28 | $1.05 | 2,954,600 |
| 2026-05-27 | $1.03 | 2,732,600 |
| 2026-05-26 | $1.04 | 2,980,900 |
| 2026-05-22 | $1.02 | 2,321,300 |
| 2026-05-21 | $1.02 | 5,545,300 |
| 2026-05-20 | $1.01 | 18,782,800 |
| 2026-05-19 | $0.89 | 15,501,800 |
| 2026-05-18 | $1.01 | 6,631,600 |
| 2026-05-15 | $1.06 | 4,820,200 |
| 2026-05-14 | $1.13 | 4,085,900 |
| 2026-05-13 | $1.18 | 4,081,200 |
| 2026-05-12 | $1.18 | 4,573,600 |
| 2026-05-11 | $1.15 | 5,541,700 |
| 2026-05-08 | $1.16 | 4,398,000 |
| 2026-05-07 | $1.18 | 11,754,300 |
| 2026-05-06 | $1.48 | 3,994,000 |
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
MarketBeat âĸ 2026-06-05T00:05:04Z
Promising Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-26T12:05:34Z
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-11T12:27:24Z
Akebia (AKBA) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T15:12:05Z
Akebia Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T13:22:25Z
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T12:50:07Z
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-06T11:45:06Z
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks âĸ 2026-04-30T19:10:00Z
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-04-29T12:25:07Z
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?
Zacks âĸ 2026-04-28T12:36:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $39,462,000 | $63,177,000 | $74,149,000 | $85,568,000 |
| Cost Of Revenue | $39,462,000 | $63,177,000 | $74,149,000 | $85,568,000 |
| Total Revenue | $236,196,000 | $160,180,000 | $194,623,000 | $292,484,000 |
| Operating Revenue | $236,196,000 | $160,180,000 | $194,623,000 | $292,484,000 |
| Expenses | ||||
| Interest Expense | $24,179,000 | $18,185,000 | $6,032,000 | $15,687,000 |
| Total Expenses | $212,697,000 | $210,594,000 | $240,698,000 | $357,330,000 |
| Other Income Expense | $-3,041,000 | $-811,000 | $182,000 | $-13,693,000 |
| Other Non Operating Income Expenses | $58,000 | $94,000 | $887,000 | $3,146,000 |
| Net Non Operating Interest Income Expense | $-24,179,000 | $-18,185,000 | $-6,032,000 | $-15,687,000 |
| Interest Expense Non Operating | $24,179,000 | $18,185,000 | $6,032,000 | $15,687,000 |
| Operating Expense | $173,235,000 | $147,417,000 | $166,549,000 | $271,762,000 |
| Other Operating Expenses | $3,396,000 | $3,220,000 | $3,237,000 | $3,175,000 |
| Selling And Marketing Expense | - | - | $100,233,000 | $138,601,000 |
| Total Other Finance Cost | - | - | - | $15,687,000 |
| General And Administrative Expense | - | - | - | $141,874,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Net Interest Income | $-24,179,000 | $-18,185,000 | $-6,032,000 | $-15,687,000 |
| Normalized Income | $-2,896,790 | $-68,505,000 | $-51,220,000 | $-77,387,000 |
| Net Income From Continuing And Discontinued Operation | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Total Operating Income As Reported | $23,499,000 | $-50,472,000 | $-46,256,000 | $-80,779,000 |
| Net Income Common Stockholders | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Net Income | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Net Income Including Noncontrolling Interests | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Net Income Continuous Operations | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Pretax Income | $-3,721,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Special Income Charges | $0 | $-575,000 | $-705,000 | $-16,839,000 |
| Operating Income | $23,499,000 | $-50,414,000 | $-46,075,000 | $-64,846,000 |
| Gross Profit | $196,734,000 | $97,003,000 | $120,474,000 | $206,916,000 |
| Per Share | ||||
| Diluted EPS | $-0.02 | $-0.33 | $-0.28 | $-0.51 |
| Basic EPS | $-0.02 | $-0.33 | $-0.28 | $-0.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $-650,790 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $24,826,000 | $-12,816,000 | $-7,561,000 | $-24,003,000 |
| Total Unusual Items | $-3,099,000 | $-905,000 | $-705,000 | $-16,839,000 |
| Total Unusual Items Excluding Goodwill | $-3,099,000 | $-905,000 | $-705,000 | $-16,839,000 |
| Reconciled Depreciation | $1,269,000 | $37,504,000 | $37,627,000 | $37,697,000 |
| EBITDA (Bullshit earnings) | $21,727,000 | $-13,721,000 | $-8,266,000 | $-40,842,000 |
| EBIT | $20,458,000 | $-51,225,000 | $-45,893,000 | $-78,539,000 |
| Diluted Average Shares | $257,157,782 | $210,946,658 | $187,465,448 | $182,782,680 |
| Basic Average Shares | $257,157,782 | $210,946,658 | $187,465,448 | $182,782,680 |
| Diluted NI Availto Com Stockholders | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Tax Provision | $1,624,000 | $0 | $0 | $0 |
| Restructuring And Mergern Acquisition | $0 | $58,000 | $181,000 | $15,933,000 |
| Gain On Sale Of Security | $-3,099,000 | $-330,000 | - | - |
| Research And Development | $62,359,000 | $37,652,000 | $63,079,000 | $129,986,000 |
| Selling General And Administration | $107,480,000 | $106,545,000 | $100,233,000 | $138,601,000 |
| Other Special Charges | - | $517,000 | $524,000 | $906,000 |
| Other Gand A | - | - | - | $141,874,000 |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-26,434,000 | $-108,229,000 | $-125,670,000 | $-125,898,000 |
| Total Assets | $376,565,000 | $220,670,000 | $241,703,000 | $356,054,000 |
| Total Non Current Assets | $123,610,000 | $106,839,000 | $123,554,000 | $170,872,000 |
| Other Non Current Assets | $59,681,000 | $37,377,000 | $12,423,000 | $5,372,000 |
| Goodwill And Other Intangible Assets | $59,044,000 | $59,044,000 | $95,086,000 | $131,128,000 |
| Current Assets | $252,955,000 | $113,831,000 | $118,149,000 | $185,182,000 |
| Other Current Assets | $3,771,000 | $7,321,000 | $5,754,000 | $32,864,000 |
| Restricted Cash | $1,699,000 | $0 | - | - |
| Prepaid Assets | $0 | $4,029,000 | $14,489,000 | - |
| Inventory | $15,610,000 | $16,243,000 | $15,691,000 | $21,568,000 |
| Receivables | $47,031,000 | $34,368,000 | $39,290,000 | $40,284,000 |
| Accounts Receivable | $47,031,000 | $34,368,000 | $39,290,000 | $40,284,000 |
| Allowance For Doubtful Accounts Receivable | $-2,691,000 | $-1,212,000 | $-1,029,000 | - |
| Gross Accounts Receivable | $49,722,000 | $35,580,000 | $40,319,000 | - |
| Cash Cash Equivalents And Short Term Investments | $184,844,000 | $51,870,000 | $42,925,000 | $90,466,000 |
| Cash And Cash Equivalents | $184,844,000 | $51,870,000 | $42,925,000 | $90,466,000 |
| Other Intangible Assets | - | - | $36,042,000 | $72,084,000 |
| Debt | ||||
| Total Debt | $51,798,000 | $47,640,000 | $48,121,000 | $99,783,000 |
| Long Term Debt And Capital Lease Obligation | $48,250,000 | $42,240,000 | $26,130,000 | $63,039,000 |
| Long Term Debt | $48,250,000 | $38,693,000 | $17,183,000 | $34,078,000 |
| Current Debt And Capital Lease Obligation | $3,548,000 | $5,400,000 | $21,991,000 | $36,744,000 |
| Current Debt | - | - | $17,500,000 | $32,000,000 |
| Other Current Borrowings | - | - | $17,500,000 | $32,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $343,955,000 | $269,855,000 | $272,287,000 | $350,824,000 |
| Total Non Current Liabilities Net Minority Interest | $181,017,000 | $188,941,000 | $172,417,000 | $221,288,000 |
| Other Non Current Liabilities | $107,181,000 | $103,512,000 | $62,898,000 | $73,201,000 |
| Derivative Product Liabilities | $2,980,000 | $5,176,000 | $0 | $760,000 |
| Current Liabilities | $162,938,000 | $80,914,000 | $99,870,000 | $129,536,000 |
| Other Current Liabilities | $86,518,000 | $6,114,000 | $4,602,000 | $6,576,000 |
| Current Deferred Liabilities | $2,681,000 | $0 | $0 | $3,738,000 |
| Payables And Accrued Expenses | $48,882,000 | $39,184,000 | $36,701,000 | $36,527,000 |
| Payables | $26,185,000 | $15,180,000 | $14,635,000 | $18,021,000 |
| Other Payable | $5,000,000 | - | - | - |
| Accounts Payable | $21,185,000 | $15,180,000 | $14,635,000 | $18,021,000 |
| Non Current Deferred Liabilities | - | $0 | $43,296,000 | $43,296,000 |
| Equity | ||||
| Common Stock Equity | $32,610,000 | $-49,185,000 | $-30,584,000 | $5,230,000 |
| Total Equity Gross Minority Interest | $32,610,000 | $-49,185,000 | $-30,584,000 | $5,230,000 |
| Stockholders Equity | $32,610,000 | $-49,185,000 | $-30,584,000 | $5,230,000 |
| Gains Losses Not Affecting Retained Earnings | $6,000 | $6,000 | $6,000 | $6,000 |
| Other Equity Adjustments | $6,000 | $6,000 | $6,000 | $6,000 |
| Retained Earnings | $-1,683,705,000 | $-1,678,360,000 | $-1,608,950,000 | $-1,557,025,000 |
| Other | ||||
| Ordinary Shares Number | $265,424,818 | $224,848,992 | $194,582,539 | $184,135,714 |
| Share Issued | $265,424,818 | $224,848,992 | $194,582,539 | $184,135,714 |
| Tangible Book Value | $-26,434,000 | $-108,229,000 | $-125,670,000 | $-125,898,000 |
| Invested Capital | $80,860,000 | $-10,492,000 | $4,099,000 | $71,308,000 |
| Working Capital | $90,017,000 | $32,917,000 | $18,279,000 | $55,646,000 |
| Capital Lease Obligations | $3,548,000 | $8,947,000 | $13,438,000 | $33,705,000 |
| Total Capitalization | $80,860,000 | $-10,492,000 | $-13,401,000 | $39,308,000 |
| Additional Paid In Capital | $1,716,307,000 | $1,629,167,000 | $1,578,358,000 | $1,562,247,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $3,547,000 | $8,947,000 | $28,961,000 |
| Long Term Provisions | $22,606,000 | $38,013,000 | $40,093,000 | $40,992,000 |
| Current Deferred Revenue | $2,681,000 | $0 | $0 | $3,738,000 |
| Current Capital Lease Obligation | $3,548,000 | $5,400,000 | $4,491,000 | $4,744,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,018,000 | $9,194,000 | $8,216,000 | $11,894,000 |
| Current Provisions | $10,291,000 | $21,022,000 | $28,360,000 | $34,057,000 |
| Current Accrued Expenses | $22,697,000 | $24,004,000 | $22,066,000 | $18,506,000 |
| Goodwill | $59,044,000 | $59,044,000 | $59,044,000 | $59,044,000 |
| Net PPE | $4,885,000 | $10,418,000 | $16,045,000 | $34,372,000 |
| Gross PPE | $4,885,000 | $10,418,000 | $16,045,000 | $34,372,000 |
| Other Properties | $4,885,000 | $10,418,000 | $16,045,000 | $34,372,000 |
| Finished Goods | $2,959,000 | $4,212,000 | $11,394,000 | $13,676,000 |
| Work In Process | $12,651,000 | $12,031,000 | $4,297,000 | $7,892,000 |
| Non Current Deferred Revenue | - | $0 | $43,296,000 | $43,296,000 |
| Accumulated Depreciation | - | - | - | $-9,319,000 |
| Leases | - | - | - | $8,687,000 |
| Machinery Furniture Equipment | - | - | - | $3,096,000 |
| Properties | - | - | - | $0 |
| Other Short Term Investments | - | - | - | - |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $59,894,000 | $-40,692,000 | $-23,384,000 | $-73,268,000 |
| Operating Activities | ||||
| Operating Cash Flow | $67,992,000 | $-40,659,000 | $-23,384,000 | $-73,154,000 |
| Cash Flow From Continuing Operating Activities | $67,992,000 | $-40,659,000 | $-23,384,000 | $-73,154,000 |
| Operating Gains Losses | $2,927,000 | $624,000 | $-760,000 | $-654,000 |
| Investing Activities | ||||
| Capital Expenditure | $-8,098,000 | $-33,000 | - | $-114,000 |
| Investing Cash Flow | $-7,926,000 | $-33,000 | $0 | $-114,000 |
| Cash Flow From Continuing Investing Activities | $-7,926,000 | $-33,000 | $0 | $-114,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $66,679,000 | $42,649,000 | $6,793,000 | $7,531,000 |
| Financing Cash Flow | $72,927,000 | $49,663,000 | $-25,206,000 | $14,598,000 |
| Cash Flow From Continuing Financing Activities | $72,927,000 | $49,663,000 | $-25,206,000 | $14,598,000 |
| Net Other Financing Charges | $-4,974,000 | $-1,272,000 | - | $40,000,000 |
| Net Common Stock Issuance | $66,679,000 | $42,649,000 | $6,793,000 | $7,531,000 |
| Common Stock Issuance | $66,679,000 | $42,649,000 | $6,793,000 | $7,531,000 |
| Repurchase Of Capital Stock | - | $-1,272,000 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-462,000 | $-37,099,000 | $-32,000,000 | $-33,000,000 |
| Issuance Of Debt | $10,000,000 | $45,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $6,080,000 | $5,035,000 | $6,059,000 | $6,755,000 |
| End Cash Position | $186,543,000 | $53,550,000 | $44,579,000 | $93,169,000 |
| Beginning Cash Position | $53,550,000 | $44,579,000 | $93,169,000 | $151,839,000 |
| Changes In Cash | $132,993,000 | $8,971,000 | $-48,590,000 | $-58,670,000 |
| Proceeds From Stock Option Exercised | $1,684,000 | $385,000 | $1,000 | $67,000 |
| Net Issuance Payments Of Debt | $9,538,000 | $7,901,000 | $-32,000,000 | $-33,000,000 |
| Net Long Term Debt Issuance | $9,538,000 | $7,901,000 | $-32,000,000 | $-33,000,000 |
| Long Term Debt Payments | $-462,000 | $-37,099,000 | $-32,000,000 | $-33,000,000 |
| Long Term Debt Issuance | $10,000,000 | $45,000,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-7,807,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-7,807,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-119,000 | $-33,000 | $0 | $-114,000 |
| Sale Of PPE | $172,000 | $0 | $0 | - |
| Purchase Of PPE | $-291,000 | $-33,000 | $0 | $-114,000 |
| Change In Working Capital | $16,472,000 | $-39,676,000 | $-20,727,000 | $-1,443,000 |
| Change In Other Working Capital | $2,681,000 | - | $-3,738,000 | $4,654,000 |
| Change In Other Current Liabilities | $-5,511,000 | $-10,695,000 | $-10,654,000 | $4,588,000 |
| Change In Other Current Assets | $-2,622,000 | $622,000 | $-1,361,000 | $-5,623,000 |
| Change In Payables And Accrued Expense | $51,612,000 | $-14,141,000 | $-15,265,000 | $-36,504,000 |
| Change In Accrued Expense | $48,530,000 | $-12,777,000 | $-10,021,000 | $-38,005,000 |
| Change In Payable | $3,082,000 | $-1,364,000 | $-5,244,000 | $1,501,000 |
| Change In Account Payable | $3,082,000 | $-1,364,000 | $-5,244,000 | $1,501,000 |
| Change In Prepaid Assets | $7,579,000 | $8,893,000 | $11,839,000 | $1,058,000 |
| Change In Inventory | $-23,125,000 | $-28,401,000 | $-2,542,000 | $19,087,000 |
| Change In Receivables | $-14,142,000 | $4,046,000 | $994,000 | $11,297,000 |
| Changes In Account Receivables | $-14,142,000 | $4,046,000 | $994,000 | $11,297,000 |
| Other Non Cash Items | $37,402,000 | $17,440,000 | $1,504,000 | $-62,619,000 |
| Stock Based Compensation | $11,283,000 | $7,775,000 | $9,317,000 | $17,849,000 |
| Asset Impairment Charge | $3,984,000 | $5,084,000 | $1,580,000 | $30,242,000 |
| Depreciation Amortization Depletion | $1,269,000 | $37,504,000 | $37,627,000 | $37,697,000 |
| Depreciation And Amortization | $1,269,000 | $37,504,000 | $37,627,000 | $37,697,000 |
| Amortization Cash Flow | $0 | $36,042,000 | $36,042,000 | $36,043,000 |
| Amortization Of Intangibles | $0 | $36,042,000 | $36,042,000 | $36,043,000 |
| Depreciation | $1,269,000 | $1,462,000 | $1,585,000 | $1,654,000 |
| Gain Loss On Investment Securities | $3,099,000 | $330,000 | $-760,000 | $-1,060,000 |
| Gain Loss On Sale Of PPE | $-172,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-5,345,000 | $-69,410,000 | $-51,925,000 | $-94,226,000 |
| Common Stock Payments | - | $-1,272,000 | $0 | - |
| Provisionand Write Offof Assets | - | $4,208,000 | $1,580,000 | $30,242,000 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Amortization Of Securities | - | - | - | $0 |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-06-01